YieldMax AI & Tech Portfolio Option Income ETF vs Neurocrine Biosciences Inc — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $42.64 (market cap $135.69M), while Neurocrine Biosciences Inc trades at $142.6 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 105.8× YieldMax AI & Tech Portfolio Option Income ETF's market cap, and YieldMax AI & Tech Portfolio Option Income ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax AI & Tech Portfolio Option Income ETF for 60 Days and Neurocrine Biosciences Inc for 23 Days on average.
| GPTY | NBIX | |
|---|---|---|
Market Cap | $135.69M | $14.36B |
Volume | 97,442 | 1,237,180 |
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $185.50 |
52-Week Low | $34.73 | $123.10 |
Typical Hold Time | 60 Days | 23 Days |
Enterprise Value | — | $14.37B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →